CLINICAL TRIALS PROFILE FOR CAMOSTAT

Clinical Trials for Camostat

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT04321096 ↗	The Impact of Camostat Mesilate on COVID-19 Infection	Recruiting	University of Aarhus	Phase 1/Phase 2	SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease presentation which has now been named COVID-19. The virus has subsequently spread throughout the world and was declared a pandemic by the World Health Organisation on 11th March 2020. As of 18 March 2020, there are 198,193 number of confirmed cases with an estimated case-fatality of 3%. There is no approved therapy for COVID-19 and the current standard of care is supportive treatment. SARS-CoV-2 exploits the cell entry receptor protein angiotensin converting enzyme II (ACE-2) to access and infect human cells. The interaction between ACE2 and the spike protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat Mesilate is a potent serine protease inhibitor. Utilizing research on severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 cell entry mechanism, it has been demonstrated that SARS-CoV-2 cellular entry can be blocked by camostat mesilate. In mice, camostat mesilate dosed at concentrations similar to the clinically achievable concentration in humans reduced mortality following SARS-CoV infection from 100% to 30-35%.
NCT04338906 ↗	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	Hospital Schwabing Munich, Germany	Phase 4	Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.
NCT04338906 ↗	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	Missioklinik, Wuerzburg, Germany	Phase 4	Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.
NCT04338906 ↗	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	St. Georg Hospital Leipzig, Germany	Phase 4	Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.
NCT04338906 ↗	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	Universitätsklinikum Hamburg-Eppendorf	Phase 4	Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.

Clinical Trial Conditions for Camostat

Condition Name

Condition Name for
Intervention	Trials
Covid19	10
COVID-19	3
Coronavirus Infection	2
COVID	2

Condition MeSH

Condition MeSH for
Intervention	Trials
COVID-19	18
Coronavirus Infections	7
Severe Acute Respiratory Syndrome	6
Infection	5

Clinical Trial Locations for Camostat

Trials by Country

Trials by Country for
Location	Trials
United States	58
Germany	7
Brazil	6
South Africa	6
Argentina	5

Trials by US State

Trials by US State for
Location	Trials
California	5
Florida	3
Arizona	2
Michigan	2
North Carolina	2

Clinical Trial Progress for Camostat

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	3
Completed	3

Clinical Trial Sponsors for Camostat

Sponsor Name

Sponsor Name for
Sponsor	Trials
Stanford University	3
Heinrich-Heine University, Duesseldorf	2
Yale University	2

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	36
Industry	12
NIH	1